2.80
+9.37%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pulmonx
From its filings with the US Securities and Exchange Commission
Pulmonx is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LUNG. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $90.5m and a net loss of $54.0m. At that date it held total assets of $129.3m and shareholders' equity of $54.1m. By region, United States accounted for 63.0%, followed by Europe, Middle-East and Africa (“EMEA”) at 29.8% and Asia Pacific at 6.9%.
We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). Our solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. Patients with severe emphysema generally experience a worse quality of life than patients with lung cancer, and we believe there is both an urgent clinical need and a strong market opportunity for a solution that is safe, effective and minimally invasive.
In 2018, we received pre-market approval (“PMA”) from the U.S. Food and Drug Administration (“FDA”). The Zephyr Valve is now commercially available in numerous countries globally. We have established reimbursement in major markets in North America, Europe and Asia Pacific and the Zephyr Valve has been included in treatment guidelines for COPD worldwide.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Oct 2020
- Employees
- 296
- Head office
- 700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Dana MeadIndependent Chairman of Board$199,990
- Mr. Glendon FrenchPresident, Chief Executive Officer, Director, since 2014$330,786
- Dr. Derrick SungChief Financial Officer, Chief Operating Officer, since 2025$2.7m
- Mr. David LehmanGeneral Counsel$1.5m
- Mr. Geoffrey RoseChief Commercial Officer$2.0m
- Mr. Thomas BurnsIndependent Director$157,490
- Mr. Richard FerrariIndependent Director$169,990
- Mr. Daniel FlorinIndependent Director$177,490
- Ms. Georgia GarinoismelenikiotouIndependent Director$169,990
- Ms. Tiffany SullivanIndependent Director$154,990
- Mr. Brian JohnstonInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 23
- Environment
- 4
- Social
- 37
- Governance
- 27
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pulmonx Corp has several notable strengths:
Weaknesses
- Pulmonx Corp faces the following weaknesses:
Opportunities
- Pulmonx Corp can explore the following opportunities:
Threats
- Pulmonx Corp should be aware of the following threats:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.